CVE:ZOM - Zomedica Pharmaceuticals Stock Price, News & Analysis

C$0.56
+0.21 (+57.75 %)
(As of 09/17/2019 03:09 PM ET)
Today's Range
C$0.56
Now: C$0.56
C$0.56
50-Day Range
C$0.29
MA: C$0.34
C$0.56
52-Week Range
C$0.29
Now: C$0.56
C$2.83
Volume10,000 shs
Average Volume8,977 shs
Market CapitalizationC$60.50 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone734-369-2555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.04 per share
Book ValueC($0.04) per share

Profitability

Miscellaneous

Employees27
Market CapC$60.50 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.


Zomedica Pharmaceuticals (CVE:ZOM) Frequently Asked Questions

What is Zomedica Pharmaceuticals' stock symbol?

Zomedica Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ZOM."

How were Zomedica Pharmaceuticals' earnings last quarter?

Zomedica Pharmaceuticals Corp (CVE:ZOM) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.05. View Zomedica Pharmaceuticals' Earnings History.

When is Zomedica Pharmaceuticals' next earnings date?

Zomedica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Zomedica Pharmaceuticals.

What is the consensus analysts' recommendation for Zomedica Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zomedica Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zomedica Pharmaceuticals.

Has Zomedica Pharmaceuticals been receiving favorable news coverage?

News articles about ZOM stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zomedica Pharmaceuticals earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Zomedica Pharmaceuticals.

Who are some of Zomedica Pharmaceuticals' key competitors?

What other stocks do shareholders of Zomedica Pharmaceuticals own?

Who are Zomedica Pharmaceuticals' key executives?

Zomedica Pharmaceuticals' management team includes the folowing people:
  • Mr. Gerald L. Solensky Jr., Chairman, Pres & CEO (Age 45)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 52)
  • Dr. Stephanie Morley D.V.M., DVM, COO & VP of Product Devel. (Age 44)
  • Mr. Michael Schilk, VP of Sales
  • Mr. David Eaton, VP of Marketing

How do I buy shares of Zomedica Pharmaceuticals?

Shares of ZOM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Zomedica Pharmaceuticals' stock price today?

One share of ZOM stock can currently be purchased for approximately C$0.56.

How big of a company is Zomedica Pharmaceuticals?

Zomedica Pharmaceuticals has a market capitalization of C$60.50 million. Zomedica Pharmaceuticals employs 27 workers across the globe.View Additional Information About Zomedica Pharmaceuticals.

What is Zomedica Pharmaceuticals' official website?

The official website for Zomedica Pharmaceuticals is http://www.zomedica.com/.

How can I contact Zomedica Pharmaceuticals?

The company can be reached via phone at 734-369-2555.


MarketBeat Community Rating for Zomedica Pharmaceuticals (CVE ZOM)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  58
MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZOM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: Day Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel